Intravenous immunoglobulin and Alzheimer's disease immunotherapy

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 1, 2007, Pages 79-85

  Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Amyloid pathology; Cognitive behavior; Human IVIg; Immunotherapy; Passive immunization

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BAPINEUZUMAB; IMMUNOGLOBULIN; PARAPROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLOOD DONOR; CELL MIGRATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; ENCEPHALITIS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LOW DRUG DOSE; MENINGOENCEPHALITIS; MICROGLIA; MOLECULAR MECHANICS; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; REPEATED DRUG DOSE; REVIEW; WITHDRAWAL SYNDROME;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY;

EID: 34047117766     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Van Leuven F: Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol (2000) 61(3):305-312.
2. Solomon B: Immunological approaches as therapy for Alzheimer's disease. Exp Opin Biol Ther (2002) 2(8):907-917.
3. Imbimbo BP: β-Amyloid immunization approaches for Alzheimer's disease. Drug Dev Res (2002) 56:150-162.
4. Monsonego A, Weiner HL: Immunotherapeutic approaches to Alzheimer's disease. Science (2003) 302(5646):834-838.
5. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D et al: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400(6740):173-177. • The first demonstration that immunization of APP-Tg mice with Aβ clears amyloid.
6. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT et al: Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408(6815):979-982. • Lowering Aβ by immunotherapy improves cognitive behavior in AD.
7. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K et al: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408(6815):982-985. • Lowering Aβ by immunotherapy improves cognitive behavior in AD.
8. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 6(8):916-919. •This study was the first to demonstrate that passive administration of Aβ-specific antibody can clear amyloid plaques in vivo.
9. Demattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (2001) 98(15):8850-8855. • This study was the first to demonstrate that peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance without crossing the blood-brain barrier.
10. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D: Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 24(27):6144-6151.
11. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science (2002) 298(5597):1379.
12. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D: Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 1(1):24.
13. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DH et al: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid-β. J Neurosci (2005) 25(3):629-636.
14. Solomon B, Koppel R, Frankel D, Hanan-Aharon E: Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci USA (1997) 94(8):4109-4112.
15. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P Schenk D, Hyman BT: Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 7(3):369-372 .
16. -/- knock-out mice. J Neurosci (2003) 23(24):8532-8538.
17. Frenkel D, Solomon B, Benhar I: Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single-chain antibody. J Neuroimmunol (2000) 106(1-2):23-31.
18. Lue L-F, Walker DG: Modeling Alzheimer's disease immune therapy mechanisms: Interactions of human postmortem microglia with antibody-opsonized amyloid β peptide. J Neurosci Res (2002) 70(4):599-610.
19. Demattos RB, Bales KR, Cummins DJ, Paul, SM, Holtzman DM: Brain to plasma amyloid-β efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 295(5563):2264-2267.
20. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science (2002) 297(5580):353-356.
21. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF et al: Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology (2003) 61(1):46-54.
22. Weksler MEP: The immunotherapy of Alzheimer's disease. Immun Ageing (2004) 1(1):2.
23. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat Med (2003) 9(4):448-452.
24. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D: Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 64(1):129-131.
25. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F: Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol (2004) 14(1):11-20.
26. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA et al: Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38(4):547-554.
27. Grubeck-Loebenstein B, Blasko I, Marx FK, Trieb I: Immunization with β-amyloid: Could T-cell activation have a harmful effect? Trends Neurosci (2000) 23(3):114.
28. Marx F, Blasko I, Zisterer K, Grubeck-Loebenstein B: Transfected human B cells: A new model to study the functional and immunostimulatory consequences of APP production. Exp Gerontol (1999) 34(6):783-795.
29. Trieb K, Ransmayr G, Sgonc R, Lassmann H, Grubeck-Loebenstein B: APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging (1996) 17(4):541-547.
30. Ulvestad E, Williams K, Matre R, Nyeland H, Olivier A, Antel J: Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets. J Neuropathol Exp Neuro (1994) 53(1):27-36.
31. Rohn TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH: A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis. J Neurochem (2000) 74(6):2331-2342.
32. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE et al: Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 21(3):383-421.
33. Akiyama H, Arai T, Tanno E, Haga C, Ikeda K: Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord (2000) 14(Suppl 1): S47-S53.
34. Bruce-Keller AJ, Estus S: Concern over the amyloid vaccine: Amyloid heterogeneity and Fc receptor signaling. Neurobiol Aging (2002) 23(5):667-670.
35. Das P, Golde TE: Open peer commentary regarding Aβ immunization and CNS inflammation. Neurobiol Aging (2002) 23(5):671-674.
36. Bajtay Z, Falus A, Erdei A, Gergely J: Fc γ R-dependent regulation of the biosynthesis of complement C3 by murine macrophages: The modulatory effect of IL-6. Scand J Immunol (1992) 35(2):195-201.
37. Tang T, Rosenkranz A, Assmann KJ, Goodman MJ, Gutierrez-Ramos JC, Carroll MC, Cotran RS, Mayadas TN: A role for Mac-1 (CD11b/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcγ receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J Exp Med (1997) 186(11):1853-1863.
38. van Spriel AB, Leusen JH, van Egmond M, Dijkman HB, Assmann KJ, Mayadas TN, van de Winkel JG: Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood (2001) 97(8):2478-2486.
39. Benveniste EN, Nguyen V, O'Keefe GM: Immunological aspects of microglia: Relevance to Alzheimer's disease. Neurochem Int (2001) 39(5-6):381-391.
40. Emmerling MR, Watson MD, Raby CA, Spiegel K: The role of complement in Alzheimer's disease pathology. Biochim Biophys Acta (2000) 1502(1):158-171.
41. Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL: Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA (2001) 98(18):10273-10278.
42. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling, R, Selkoe DJ, Weiner HL: Increased T cell reactivity to amyloid β-protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 112(3):415-422.
43. Selkoe DJ: Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev (2001) 81(2):741.
44. Berger M: A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep (2002) 2(5):368-378.
45. Dalakas MC: Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology (2002) 59(12 Suppl 6):S13-S21.
46. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 345(10):747-755.
47. Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci (2002) 23(Suppl 1):S1-S8.
48. Ballow M: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol (1997) 100(2):151-157.
49. Sewell WA, North ME, Cambronero R, Webster AD, Farrant J: In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol (1999) 116(3):509-515.
50. Prasad NKA, Papoff G, Zeune A, Bonnin E, Kazatchkine MD, Ruberti G, Kaver SV: Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol (1998) 161(7):3781-3790.
51. Istrin G, Bosis E, Solomon B: Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide. J Neurosci Res (2006) 84(2):434-443 • The first insight into the clearance of Aβ peptide by IVIg.
52. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F: Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol (1990) 27(2-3):229-237.
53. Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, Kettenmann H: An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res (1992) 31(4):616-621.
54. Gan L, Ye S, Chu A, Anton K, Yi S, Vincent VA, von Schack D, Chin D, Murray J, Lohr S, Patthy L et al: Identification of cathepsin B as a mediator of neuronal death induced by Aβ-activated microglial cells using a functional genomics approach. J Biol Chem (2004) 279(7):5565-5572.
55. Koenigsknecht-Talboo J, Landreth GE: Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci (2005) 25(36):8240-8249.
56. Sedgwick JD, Schwender S, Imrich H, Dorries R, Butcher GW, ter Meulen V: Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci USA (1991) 88(16):7438-7442.
57. Licastro F, Mallory M, Hansen LA, Masliah E: Increased levels of α-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol (1998) 88(1-2):105-110.
58. Streit WJ: Microglia as neuroprotective, immunocompetent cells of the CNS. Glia (2002) 40(2):133-139.
59. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, Hemmer B et al: Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease. Ann Neurol (2002) 52(2):253-256. • The first demonstration of the presence of effective antibodies against Aβ peptide in IVIg preparations.
60. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M: Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity. Brain (2003) 126(9):1935-1939.
61. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S: Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology (2001) 57(5):801-805.
62. Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE: Autoantibodies to redox-modified oligomeric Aβ are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem (2005) 280(17):17458-17463.
63. Weksler ME, Gouras G, Relkin NR, Szabo P: The immune system, amyloid-β peptide, and Alzheimer's disease. Immunol Rev (2005) 205:244-256.
64. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P: Patients with Alzheimer disease have lower levels of serum antiamyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 37(7):943-948.
65. Xu S, Gaskin F: Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev (1997) 94(1-3):213-222.
66. Weksler ME: The immunotherapy of Alzheimer's disease. Immun Ageing (2004) 1(1):2.
67. Brekke OH, Loset GA: New technologies in therapeutic antibody development. Curr Opin Pharmacol (2003) 3(5):544-550.
68. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A et al: Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 75(10):472-1474.
69. Elan Corp plc: Elan Reports First Quarter 2005 Financial Results. Press Release (2005):April 28
70. Phase II study of intravenous immunoglobulin (IVIg) for Alzheimer's disease. ClinicalTrials.gov, MD, USA (March 2006). http://www. clinicaltrials.gov/ct/show/NCT00299988 • The overall goal of this double-blind phase II study is to evaluate the safety, efficacy and biological mechanisms of action of IVIg in the treatment of mild to moderate stage AD.